Issues
-
Cover Image
Cover Image
The gut microbiome contributes to antitumor immune responses and the efficacy of immune checkpoint inhibition (ICI) in cancer patients. Here, the Okuma, Routy, and Zitvogel labs study how previous antibiotic treatment impacts ICI efficacy in 70 non–small cell lung cancer (NSCLC) patients. Performing 16S rRNA V3–V4 sequencing of fecal samples, they found that NSCLC patients with pre-ICI antibiotic treatment had less bacterial alpha-diversity, but enrichment of Ruminococcaceae UCG 13 and Agathobacter, in the gut. These alterations correlate to dampened ICI efficacy. Thus, antibiotic treatment negatively impacts ICI efficacy in NSCLC patients. To read more, Hakozaki et al. begins on page 1243. Taxonomic cladogram of the gut microbiota of patients treated with or without antibiotics from the Okuma laboratory. Artwork by Lewis Long. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Immunology Research
Cancer Immunology Research, launched in 2013 with Glenn Dranoff as founding Editor-in-Chief, is published by the AACR. The Journal illuminates the interplay between tumors and the immune system, with Robert D. Schreiber and Philip D. Greenberg serving as the Editors-in-Chief.
Table of Contents
What We’re Reading
Cancer Immunology at the Crossroads
Cancer Immunology Miniatures
Association of Probiotic Clostridium butyricum Therapy with Survival and Response to Immune Checkpoint Blockade in Patients with Lung Cancer
Research Articles
The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non–Small Cell Lung Cancer
The Gut Microbiome Is Associated with Clinical Response to Anti–PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer
Hyperglycemia Enhances Cancer Immune Evasion by Inducing Alternative Macrophage Polarization through Increased O-GlcNAcylation
Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity
Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma
Journal Archive
Cancer Immunology Research
(2013-Present)Published monthly since 2013.
(ISSN 2326-6066)
Cancer Immunity
(2001-2013; volumes 1-13)Published periodically from 2001-2013.
(EISSN 1424-9634)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.